QDEL QuidelOrtho Stock Outlook 2026: Merger Debt Versus the Post-COVID Testing Reset
QuidelOrtho (QDEL) 2026 stock outlook: how the Quidel and Ortho Clinical Diagnostics merger built a four-segment diagnostics portfolio spanning immunoassay, clinical chemistry, transfusion medicine, and point-of-care molecular testing, why merger debt and COVID-normalization risk are pressuring the multiple, a peer comparison against Abbott, BD, and bioMérieux, and a US-investor tax and monitoring framework.